Canadian Patient Dosed in Argenx DOK7-CMS Study
Our clinical research team at the NeuroMuscular centre of The Ottawa Hospital is excited to share that a Canadian patient affected by DOK-7 Congenital Myasthenic Syndrome (CMS) is the first patient world-wide to be dosed in a global placebo-controlled trial investigating a novel medicine for this neuromuscular condition.
Phase 1 Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK-7 CMS
The drug was administered as a part of the global Phase 1 Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK-7 CMS, sponsored by Argenx. The international Phase 1 study examines the safety and tolerability of ARGX-119 in adult participants with DOK7- CMS, and assesses pharmacokinetics, immunogenicity, and how it may improve the way patients feel and function.
“We are delighted to lead the way in delivering the first dose to a participant in this multi-centre study, and are excited to provide an opportunity for Canadians and patients worldwide with DOK7-CMS to access a potentially disease-modifying therapy” said Lead Investigator, Dr Hanns Lochmüller. “As a Canadian site, we are proud to showcase the efficiency, organization, and trial capacity of Canada’s clinical research centres to conduct neuromuscular clinical trials.”
Lochmüller Lab Clinical Research
The study is currently active and recruiting patients. For more information about our clinical trial activities in Ottawa, please visit our clinical research webpage. For a complete list of currently recruiting Canadian neuromuscular clinical trials, please visit the NMD4C Clinical Trials Database.
Read next...
New Publication: Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes
We are recruiting: Postdoctoral Fellow in Rare Disease Bioinformatics
Oral Platform Presentation (Undergraduate) Category Winner!
